Liberum Capital reaffirmed their buy rating on shares of Relx (LON:REL) in a report released on Friday, ThisIsMoney.Co.Uk reports.

Other research analysts also recently issued reports about the stock. UBS Group downgraded shares of ResMed from a buy rating to a neutral rating in a research report on Tuesday, July 16th. JPMorgan Chase & Co. set a $195.00 price objective on shares of bluebird bio and gave the stock a buy rating in a research report on Friday, May 17th. Goldman Sachs Group raised shares of Las Vegas Sands to a buy rating in a research report on Tuesday, June 11th. Finally, Deutsche Bank raised their price objective on shares of Spirit Airlines from $75.00 to $79.00 and gave the stock a buy rating in a research report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of GBX 1,860.25 ($24.31).

Shares of Relx stock opened at GBX 1,956 ($25.56) on Friday. Relx has a 1 year low of GBX 1,466.50 ($19.16) and a 1 year high of GBX 1,984.50 ($25.93). The company has a debt-to-equity ratio of 270.50, a current ratio of 0.44 and a quick ratio of 0.36. The stock has a market cap of $38.06 billion and a P/E ratio of 27.39. The stock’s fifty day simple moving average is GBX 1,927.62.

The company also recently announced a dividend, which will be paid on Monday, September 2nd. Stockholders of record on Thursday, August 1st will be paid a GBX 13.60 ($0.18) dividend. This represents a dividend yield of 0.73%. The ex-dividend date of this dividend is Thursday, August 1st. Relx’s dividend payout ratio (DPR) is presently 0.59%.

Relx Company Profile

RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.

Featured Article: What is a stock portfolio tracker?

Analyst Recommendations for Relx (LON:REL)

Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.